TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07049575: Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Sponsor: Incyte Corporation · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 24 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$1,245,624

Rescue Site Savings

+$824,568

Unlock Full NCT07049575 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07049575 Rescue Dossier →